Oxazepam
Oxazepam is a short- to intermediate-acting benzodiazepine used for the short-term relief of anxiety and associated insomnia.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It enhances the inhibitory action of GABA at the GABA-A receptor, increasing chloride conductance to produce anxiolytic, sedative and hypnotic effects.
Prescribing in practice
- Benzodiazepines should be used at the lowest effective dose for the shortest possible period because of the risk of tolerance, dependence and a withdrawal syndrome.
- There is additive sedation and respiratory depression with alcohol, opioids and other CNS depressants.
- Because it does not require oxidative hepatic metabolism, oxazepam is sometimes preferred in hepatic impairment and in the elderly, but caution and reduced exposure are still warranted.
Monitoring
Review the ongoing need for treatment regularly and monitor for excessive sedation, falls and emerging dependence.
Counselling the patient
- This medicine can cause drowsiness; avoid driving or operating machinery if affected.
- Do not drink alcohol while taking oxazepam.
- Do not stop suddenly after regular use; your prescriber will arrange a gradual reduction.
Evidence & guidelines
NICE and MHRA guidance support short-term, lowest-effective use of benzodiazepines such as oxazepam for anxiety because of the risk of dependence.
Reference: NICE TA77; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Benzodiazepine Conversion Calculator · Drug Conversion
- Cervical Cerclage Criteria (Short Cervix / Preterm Risk) · Preterm Labour
- Withdrawal Assessment Tool (WAT-1) for Paediatric Iatrogenic Withdrawal · Critical Care
- Brief Pain Inventory — Short Form (BPI-SF) · Pain
- CIWA-Ar — Alcohol Withdrawal Scale · Diagnosis
- Montreal Cognitive — Short Screening for Substance Misuse · Substance Misuse Screening
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185